Wire flash
Trump's 'favored nations' drug discount secures buy-in from all 50 states, saving billions for Medicaid
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
The New York Post reports that former President Donald Trump's 'favored nations' drug pricing model has secured participation from all 50 U.S. states, a policy expected to generate billions of dollars in savings for the Medicaid program. The announcement was covered by multiple outlets including AP News, Axios, and The New York Times. However, The Washington Post reported that secret contracts have revealed undisclosed terms in the drug-pricing deals, raising questions about the full scope and implications of the agreements. The policy aims to lower prescription drug costs for state Medicaid programs by tying prices to those paid by other developed nations.
Source report
Multiple news outlets report that the Trump administration’s Medicaid drug pricing initiative has secured buy-in from every U.S. state, promising significant savings for the program.
Key Developments
- All 50 states have agreed to participate in the Trump administration’s “favored nations” drug discount model for Medicaid, according to reports from the New York Post, AP News, and Axios.
- The model is expected to save billions of dollars for Medicaid by tying drug prices to lower rates paid in other developed countries.
- President Trump announced the unanimous state participation, framing it as a major step toward reducing prescription drug costs for government healthcare programs.
Coverage Highlights
| Source | Headline | |--------|----------| | New York Post | “Trump’s ‘favored nations’ drug discount gets buy-in from all 50 states — and will save billions for Medicaid” | | AP News | “Trump announces all 50 states are joining Medicaid drug pricing model” | | Axios | “Trump announces cheaper drugs for state Medicaid programs” | | The New York Times | “Trump Promotes Program to Reduce Medicaid Drug Prices” | | The Washington Post | “Secret contracts reveal undisclosed terms in Trump’s drug-pricing deals” |
Additional Context
- The Washington Post reports that secret contracts have revealed undisclosed terms in the drug-pricing deals, raising questions about transparency.
- The New York Times notes that the program is being promoted by President Trump as a mechanism to lower drug costs for state Medicaid programs.
Note: This summary compiles reporting from multiple major news outlets as of the original publication date.
Source
Top stories - Google NewsWestern